| Literature DB >> 11206477 |
M Matsushita1, T Z Hoffman, J A Ashley, B Zhou, P Wirsching, K D Janda.
Abstract
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11206477 DOI: 10.1016/s0960-894x(00)00659-4
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823